Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid - Full Text View

Sponsored by:	Sanofi-Aventis
Information provided by:	Sanofi-Aventis
ClinicalTrials.gov Identifier:	NCT00174733

Purpose

To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.

Condition	Intervention	Phase
Asthma	Drug: Ciclesonide	Phase III

MedlinePlus related topics: Asthma

Drug Information available for: Corticosteroids Ciclesonide Phenylephrine Guaifenesin Naphazoline Naphazoline hydrochloride Oxymetazoline Oxymetazoline hydrochloride Phenylephrine hydrochloride Phenylpropanolamine Phenylpropanolamine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered for Twelve Weeks Either in a Once-Daily Regimen in the Morning (160 μg qd AM) or in a Twice Daily Regimen (80 μg Bid) in Adults and Adolescents With Mild to Moderate Persistent Asthma Treated Previously With Inhaled Corticosteroids

Further study details as provided by Sanofi-Aventis:

Primary Outcome Measures:

Change from baseline to Week 12 in FEV1

Secondary Outcome Measures:

Symptom scores, rescue albuterol use and morning peak flow measurements

Estimated Enrollment:	447
Study Start Date:	July 2005
Estimated Study Completion Date:	August 2006

Eligibility

Ages Eligible for Study:	12 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males or females 12 years or older
History of persistent bronchial asthma for at least 6 months
Documented use of an inhaled steroid or a combination of an inhaled steroid/long-acting beta 2 agonist for at least 1 month before screening
At screening, FEV1 of 60 to 90% predicted or 70 to 95% predicted for either ICS or ICS/LABA use respectively.Reversibility of FEV1 by at least 12% and 200 ml post-bronchodilator
Be able to use oral inhalers
Non-smokers

Exclusion Criteria:

History of life-threatening asthma
Other pulmonary diseases; URI within 4 weeks before screening
Use of systemic steroids within 1 month before screening or more than 3 times in previous 6 months
Beta-adrenergic blocking agent use
More than 2 in-patient hospitalizations or ER visits due to asthma exacerbations in the prior year before screening
Pregnant or breast-feeding females
Females of child-bearing potential not using adequate means of birth control
Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease
Abnormal clinical laboratory parameters that would limit participation in the study or interfere with interpretation of study results
History of drug or alcohol abuse
Treatment with any investigational product within 30 days prior to study entry

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00174733

Locations

United States, New Jersey
Sanofi-Aventis
Bridgewater, New Jersey, United States, 08807

Sponsors and Collaborators

Sanofi-Aventis

More Information

Related Info This link exits the ClinicalTrials.gov site

Study ID Numbers:	EFC6163, XRP 1526B/3030
Study First Received:	September 13, 2005
Last Updated:	October 20, 2006
ClinicalTrials.gov Identifier:	NCT00174733
Health Authority:	United States: Food and Drug Administration

Keywords provided by Sanofi-Aventis:

Glucocorticosteroid. Bronchospasm

Study placed in the following topic categories:

Bronchial Spasm
Ciclesonide
Asthma
Naphazoline
Oxymetazoline
Lung Diseases, Obstructive
Hypersensitivity

Respiratory Tract Diseases
Guaifenesin
Phenylephrine
Lung Diseases
Hypersensitivity, Immediate
Phenylpropanolamine
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases
Bronchial Diseases
Therapeutic Uses
Anti-Allergic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009